42 results about "Chiro-inositol" patented technology

The invention discloses an inositol dehydrogenase mutant and a preparation method of D-chiral inositol, and belongs to the technical field of genetic engineering. The inositol dehydrogenase mutant is obtained by mutating an amino acid sequence as shown in SEQ ID NO.2 through the following mutations: the 200th amino acid is mutated into C from V, the 234th amino acid is mutated into Q from V, and the 256th amino acid is mutated into E from R. According to the invention, the amino acid sequence of wild type inositol dehydrogenase is mutated to obtain the inositol dehydrogenase mutant which is a high-activity mutant capable of catalyzing conversion of myo-inositol into 2-keto-myo-inositol; therefore, when the inositol dehydrogenase mutant and keto isomerase act together to prepare D-chiral inositol by taking myo-inositol as a substrate, the yield of the D-chiral inositol is effectively improved.

The invention discloses a D-pinitol dehydrogenase MtOEPa mutant and application thereof, and belongs to the technical field of gene engineering. The D-pinitol dehydrogenase MtOEPa mutant is obtained by carrying out any one of the following mutations (A)-(F) on an amino acid sequence shown as SEQ ID NO.1: (A) mutating the 87th amino acid from I into A; (B) the 87th amino acid is mutated from I to A, and the 40th amino acid is mutated from N to A; (C) the 87th amino acid is mutated from I to A, and the 160th amino acid is mutated from P to S; (D) the 87th amino acid is mutated from I to A, and the 200th amino acid is mutated from S to A; (E) the 87th amino acid is mutated from I to A, and the 219th amino acid is mutated from F to Y; (F) the 87th amino acid is mutated into A from I, the 160th amino acid is mutated into S from P, and meanwhile, the 219th amino acid is mutated into Y from F. The stability of the D-pinitol dehydrogenase MtOEPa mutant disclosed by the invention is improved, so that the yield of D-chiro-inositol is improved.

The invention discloses a keto isomerase mutant as well as a preparation method and application thereof, and relates to the technical field of gene engineering. The keto isomerase mutant is obtained by performing the following mutations on an amino acid sequence shown as SEQ ID NO.2: the 34th amino acid is mutated from N to R; meanwhile, the 188th amino acid is mutated from I to K. The half-life period of the keto isomerase mutant obtained by mutating the amino acid sequence shown in SEQ ID NO.2 is prolonged, and the enzyme activity is improved, so that the yield of D-chiro-inositol is further improved.

The invention discloses a composition containing D-chiro-inositol as well as a preparation method and application of the composition. The composition comprises D-chiro-inositol, Myo-inositol and microcapsule powder, wherein the wall material of the microcapsule powder consists of anhydride modified edible protein and a polysaccharide compound; the edible protein is selected from at least one of spirulina protein, quinoa protein, whey protein and soybean protein; the polysaccharide compound comprises at least one of fucoidin and larch arabinogalactan. Active components are also embedded in the microcapsule powder, and comprise at least one of Omega-3, coenzyme Q10, astaxanthin and vitamin. According to the composition, the stability and bioavailability of fat-soluble active ingredients are improved through microencapsulation, and the composition has a synergistic effect with components such as D-chiro-inositol and Myoinositol, so that insulin resistance is effectively improved, female hormone balance is adjusted, and polycystic ovarian syndrome is improved. The process is simple, is suitable for large-scale production, and can be widely applied to dietary supplements or functional foods.

The invention relates to the technical field of livestock and poultry breeding, in particular to a goat hybridization breeding method capable of achieving complete-cycle nutrition enhancement. The core of the method is that systematic nutrition intervention runs through the whole breeding process. Before hybridization, performing differential nutrition pretreatment on the parents for 60 days: feeding the female parents with a breeding nutrition enhancer added with components such as D-chiro-inositol and N-acetylcysteine, and supplementing sperm motility enhancer containing acetylated L-carnitine and ergothioneine to the male parents. In the gamete treatment stage, the oocytes are subjected to in-vitro maturation culture in a special culture solution containing components such as D-chiro-inositol and a growth differentiation factor 9; after the sperms are subjected to gradient centrifugal screening, completing in-vitro fertilization in an optimized fertilization culture solution; after the embryos develop into blastocysts in the sequential culture system, carrying out laparoscopic transplantation, and carrying out staged precise nutrition culture on the pregnant ewes. According to the method, through multi-level nutrition enhancement, the reproductive capacity of the goats and the growth performance of offspring are effectively improved.

This invention discloses a ketoisomerase mutant and a method for preparing D-chiral inositol, belonging to the field of genetic engineering technology. The ketoisomerase mutant is obtained by mutating the 73rd amino acid of the amino acid sequence shown in SEQ ID NO.3 from L to N. The ketoisomerase mutant L73N obtained by this invention further enhances enzyme activity. When catalyzing the reaction of muscle inositol to synthesize D-chiral inositol together with inositol dehydrogenase, it can further improve the conversion rate and the yield of D-chiral inositol.

This invention discloses a ketoisomerase mutant and its application in the preparation of D-chiral inositol, belonging to the field of genetic engineering technology. The ketoisomerase mutant is obtained by mutating the amino acid sequence shown in SEQ ID NO.1, specifically by mutating amino acid position 62 and / or amino acid position 175 of the amino acid sequence shown in SEQ ID NO.1. After the above-mentioned mutation of the wild-type thermostable ketoisomerase, the resulting ketoisomerase mutant not only retains the advantages of the wild-type thermostable ketoisomerase—its heat resistance and susceptibility to temperature fluctuations—but also exhibits higher enzyme activity. When co-catalyzing the reaction of muscle inositol to D-chiral inositol with inositol dehydrogenase, it can further improve the conversion rate and yield of D-chiral inositol even at high substrate concentrations.

The application discloses a D-mangiferoline dehydrogenase MtOEPa mutant and application thereof, and belongs to the technical field of genetic engineering. The amino acid sequence of the D-mangiferoline dehydrogenase MtOEPa mutant is shown as SEQ ID NO. 4. The D-mangiferoline dehydrogenase MtOEPa mutant has stronger affinity to a substrate myo-inositol, higher catalytic efficiency and higher enzyme activity, and can significantly improve the conversion rate of a reaction and the yield of D-chiro-inositol when catalyzing the reaction of myo-inositol to generate D-chiro-inositol.

This invention discloses an enzyme preparation and a method for preparing D-chiral inositol, belonging to the field of genetic engineering technology. The enzyme preparation includes inositol dehydrogenase and 2-keto-inositol isomerase. The amino acid sequence of inositol dehydrogenase is shown in SEQ ID NO. 6, and the amino acid sequence of 2-keto-inositol isomerase is shown in SEQ ID NO. 8. Compared with the prior art, the enzyme activities of the inositol dehydrogenase and 2-keto-inositol isomerase with specific amino acid sequences of this invention are further improved. When catalyzing the reaction of muscle inositol to D-chiral inositol, both can further improve the conversion rate and the yield of D-chiral inositol. Furthermore, this inositol dehydrogenase has high tolerance to muscle inositol, and can still efficiently catalyze the reaction to produce D-chiral inositol even at high substrate concentrations, alleviating substrate inhibition.

The present application relates to carbocyclic compounds, more particularly to the field of cyclohexanehexol, and particularly to a method for extracting D-chiro-inositol from Ceratonia siliqua and application thereof. The present application uses an acid hydrolysis method, takes TFA as a catalyst, and takes L-(-) camphor sulfonic acid as a specific recrystallization selection agent to obtain high-purity DCI from Ceratonia siliqua, and has the advantages of high extraction efficiency, high DCI yield, high purity, low cost, green environmental protection and the like.

The invention discloses a 2-keto-inositol isomerase mutant and application thereof, and belongs to the technical field of gene engineering. The 2-keto-inositol isomerase mutant is obtained by performing at least one of the following mutations on an amino acid sequence as shown in SEQ ID NO.1: (1) mutating the 63rd amino acid from L to A; (2) the 155th amino acid is mutated from E to R; and (3) the 210th amino acid is mutated from G to R. After the wild type 2-keto-inositol isomerase is mutated, the obtained 2-keto-inositol isomerase mutant is higher in enzyme activity, better in heat resistance and longer in half-life period, and when the D-chiral inositol is prepared by combining with inositol dehydrogenase, the reaction conversion rate and the yield of the D-chiral inositol are improved.

The invention discloses a keto isomerase mutant and application thereof, and belongs to the technical field of gene engineering. The keto isomerase mutant is obtained by performing at least one of the following mutations on an amino acid sequence as shown in SEQ ID NO.1: the 64th amino acid is mutated from S to T; and the 105th amino acid is mutated into A from G. According to the invention, after the wild-type ketoisomerase as shown in SEQ ID NO.1 is mutated, the enzyme activity of the obtained ketoisomerase mutant is further improved, so that the yield of D-chiral inositol is further improved.

This invention relates to the field of genetic engineering technology, and particularly to an enzyme preparation for the catalytic synthesis of D-chiral inositol and a method for preparing D-chiral inositol. The enzyme preparation includes inositol dehydrogenase and ketoisomerase. The amino acid sequence of the inositol dehydrogenase is any one of the sequences shown in SEQ ID NO. 23 to SEQ ID NO. 25; the amino acid sequence of the ketoisomerase is any one of the sequences shown in SEQ ID NO. 29 to SEQ ID NO. 31. This invention co-expresses inositol dehydrogenase and ketoisomerase with specific site mutations, significantly improving the conversion rate of D-chiral inositol.

The invention discloses a slow-release nutrition preparation for small needle knife guide in an ovarian reflex region and a preparation method of the slow-release nutrition preparation, and relates to the technical field of medical nutrition preparations. 20 to 30 parts of a slow release carrier; 3-6 parts of an absorption enhancer; 45 to 65 parts of a biocompatible auxiliary material; 1-3 parts of a stabilizer; according to the invention, the D-chiro-inositol is helpful for adjusting hormone balance in vivo and promoting ovarian health; glutathione is a potent antioxidant and protects ovarian cells from oxidative damage; the Q10 coenzyme can enhance cell energy metabolism and improve the ovarian function; soybean isoflavone is phytoestrogen and can simulate the action of estrogen of a human body, the core nutritional ingredients are combined with a slow release carrier prepared from chitosan, sodium alginate and a medicinal fungal polysaccharide compound, slow release of nutrient substances is achieved, action time is prolonged, bioavailability of the nutrient substances is improved, the substances are combined, and the slow release effect is achieved. The nourishing and long-acting protection on the ovary reflex region are realized.

The invention discloses a method for recovering D-chiral inositol mother liquor, and relates to the technical field of D-chiral inositol production.The method comprises the steps that ethyl alcohol is added into the D-chiral inositol mother liquor, and then cooling and suction filtration are conducted to obtain filtrate I and a solid I; adding the solid I into purified water, stirring at 50-60 DEG C for 1-2 hours, concentrating, adding ethanol, cooling, and carrying out suction filtration to obtain filtrate II and a solid II; combining the filtrate I and the filtrate II, distilling, collecting a dealcoholization solution and an ethanol recovery solution, carrying out thermal concentration on the obtained dealcoholization solution until the solid content is 45-55% w / w, adding ethanol into the obtained concentrated solution, cooling, and carrying out suction filtration to obtain a filtrate III and a solid III; and adding purified water into the solid III for dissolving, then adding 1-5% v / v of activated carbon for decoloration, then carrying out suction filtration to obtain a decolorized solution, then adding ethanol, cooling, and carrying out suction filtration to obtain a D-chiro-inositol finished product and a filtrate IV, thereby improving the yield and purity of the product.

The utility model discloses a kind of separation preparation devices of D-chiral inositol, it is related to D-chiral inositol production technical field, the outlet of conversion liquid tank is communicated with ceramic membrane device, the clear liquid outlet of ceramic membrane device is communicated with first concentrator, the outlet of first concentrator is communicated with first crystallizing tank, the outlet of first crystallizing tank is communicated with first filter, the liquid phase outlet of first filter is communicated with dealcoholization tank, the bottom outlet of dealcoholization tank is communicated with second concentrator, the outlet of second concentrator is communicated with second crystallizing tank, the outlet of second crystallizing tank is communicated with second filter, the solid phase outlet of second filter is communicated with D-chiral inositol tank. Through the series connection process of ceramic membrane filtration, twice concentration, twice crystallization and filtration, the step-by-step separation purification of D-chiral inositol is realized, using the selectivity of ethanol crystallization, effectively improve product purity.

The invention relates to the technical field of D-chiro-inositol production, in particular to a process method for preparing D-chiro-inositol by taking kasugamycin hydrochloride as a raw material, which comprises the following steps: taking kasugamycin hydrochloride as a raw material, adding a sulfated zirconium-titanium composite oxide catalyst with SO4 < 2-> loading capacity of 3M, and controlling the reaction temperature and time to prepare D-chiro-inositol. The obtained hydrolysate is filtered, the collected filtrate enters an anion resin column, the obtained effluent is subjected to nanofiltration membrane concentration and vacuum concentration treatment, ethyl alcohol is added into the collected concentrated solution, heat preservation treatment is performed for a period of time, then cooling crystallization is performed, water is added into a D-chiro-inositol crude product collected through suction filtration, stirring and dissolving are performed, then decoloration treatment is performed, and the D-chiro-inositol is obtained. Adding ethanol into the collected decoloring solution, cooling and crystallizing after crystals are separated out, and drying the collected crystals after suction filtration to obtain a D-chiro-inositol product; the process method is simple in process and simple to operate, can obtain the D-chiro-inositol product with high yield and high purity, and is suitable for industrial production.

The invention relates to the technical field of D-chiro-inositol, in particular to a method for recovering D-chiro-inositol mother liquor, which comprises the following steps: respectively collecting D-chiro-inositol secondary crystallization mother liquor and recrystallization mother liquor, adding ethanol into the recrystallization mother liquor, cooling and crystallizing, and collecting a first solid and a first filtrate; merging the secondary crystallization mother liquor and the filtrate, concentrating, decoloring and carrying out suction filtration, concentrating the collected decoloring solution, adding ethanol, cooling, crystallizing and carrying out suction filtration, and respectively collecting a second solid and a second filtrate; mixing the first solid and the second solid, adding water, heating, dissolving, decolorizing, carrying out suction filtration, adding ethanol into the collected decolorized solution, cooling, crystallizing, carrying out suction filtration, and collecting crystals and a third filtrate; and drying the collected crystals to obtain the D-chiro-inositol product. According to the process method, the D-chiro-inositol product with high purity, high content and high yield can be obtained, and resource waste is avoided.

This invention discloses an enzyme preparation and a method for preparing D-chiral inositol, belonging to the field of genetic engineering technology. The enzyme preparation includes D-monosolenol dehydrogenase MtOEPa and D-pineol dehydrogenase MtOEPb; the amino acid sequence of D-monosolenol dehydrogenase MtOEPa is shown in SEQ ID NO.6, SEQ ID NO.8, or SEQ ID NO.10; the amino acid sequence of D-pineol dehydrogenase MtOEPb is shown in SEQ ID NO.3 or SEQ ID NO.12. This invention mutates wild-type D-monosolenol dehydrogenase MtOEPa and wild-type D-pineol dehydrogenase MtOEPb. The enzyme activities of the four mutants obtained through mutation are all significantly increased, which can significantly improve the conversion rate and yield of D-chiral inositol in the catalytic reaction of muscle inositol to D-chiral inositol.

The present invention relates to orally administrated compositions suitable for supporting women with premenstrual syndrome, which compositions contain: a) stereoisomers of inositol that contribute to the normal function of the ovaries, specifically myoinositol and D-chiro-inositol in a ratio of myoinositol: D-chiro-inositol from 2:1 to 5:1; b) vitamins of the B complex that contribute to normalpsychological function, preferably folic acid and / or vitamin B2 and / or vitamin B6 and / or vitamin B12; c) osier extract and / or Rooibos extract that contribute in normal psychological function; d) N-acetylcysteine and e) one or more inactive excipients.

The invention discloses a crystallization method of large-particle D-chiro-inositol, and relates to the technical field of D-chiro-inositol production.The crystallization method comprises the steps that after a D-chiro-inositol crude product is dissolved and decolored, methyl alcohol and seed crystals are added, the temperature is lowered to 40-45 DEG C for crystallization, then the rotating speed is lowered, methyl alcohol continues to be added, nitrogen is added, airflow stirring is increased, the temperature is lowered to 20-25 DEG C, crystallization is conducted, and the large-particle D-chiro-inositol is obtained. The crystallization tank is heated to 25-30 DEG C and then cooled to 10-15 DEG C, an obtained filter cake is washed and dried, D-chiro-inositol crystals are obtained, 20-mesh oversize products are smaller than 3%, 25-mesh undersize products are smaller than 3%, more than 94% of crystal particles are 20-25 meshes, and the uniformity of the particles is high.

The present application relates to the technical field of chiral inositol, in particular to a chiral inositol crystal form and a preparation method thereof, wherein the chiral inositol crystal form has characteristic diffraction peaks at diffraction angles 2theta of 13.44±0.02°, 14.85±0.02°, 16.58±0.02°, 17.75±0.02°, 19.43±0.02°, 22.79±0.02°, 23.70±0.02°, 24.79±0.02°, 25.90±0.02°, 27.05±0.02°, 28.66±0.02°, 30.11±0.02°, 30.77±0.02°, 34.66±0.02°, 37.776±0.02°, 39.46±0.02°, 40.73±0.02°, 44.78±0.02° and 46.52±0.02°, as measured by X-ray powder diffraction analysis using Cu-Kα rays, and has high thermal stability and is more widely applicable.

This invention discloses a method for separating and preparing D-chiral inositol, relating to the field of D-chiral inositol production technology. The D-chiral inositol conversion solution is subjected to sterilization, protein removal, desalting, and concentration. Then, ethanol is added for preliminary separation. After de-alcoholization, ethanol is added again for crystallization to purify the D-chiral inositol. Finally, ethanol is added to the solution for cooling and crystallization. Ethanol is an inert solvent; adding ethanol allows more chiral inositol to crystallize from the solution, increasing the yield. Adding ethanol also reduces the viscosity of the crystallization system, improving its fluidity and allowing for more uniform crystal growth, thus improving the quality of D-chiral inositol.

The invention discloses a process method for preparing D-chiro-inositol, and relates to the technical field of biology, IDH crude enzyme liquid, KMI crude enzyme liquid and NOX crude enzyme liquid are added into an inositol solution for conversion, after conversion is finished, inactivation treatment is performed, and the mixture passes through a ceramic membrane, an ultrafiltration membrane, cationic resin, decolorizing resin and anion resin to obtain a solution I; after the solution I is subjected to nanofiltration concentration, heat concentration continues to be conducted till the volume of the solution I is one third of the volume of a nanofiltration concentrated solution, then the temperature is reduced to 25 DEG C, suction filtration is conducted, a solution II and a solid II are obtained, and the solution II is a D-chiral inositol solution; continuously performing thermal concentration on the solution II until the solid content is 40-50% w / w, adding ethanol of which the volume is 1 time that of the solution II under the condition of 50 DEG C, performing heat preservation for 2 hours, then cooling to 25 DEG C at the speed of 5 DEG C / h, and performing suction filtration to respectively obtain a solution III and a solid III; the usage amount of the enzyme is greatly reduced, the production cost is reduced, and the production efficiency is improved.

This utility model discloses a production apparatus for D-chiral inositol, relating to the field of D-chiral inositol production technology. The outlet of the conversion liquid tank is connected to a first concentration tank, the outlet of the first concentration tank is connected to a first filter, the liquid phase outlet of the first filter is connected to a second concentration tank, the inlet of the second concentration tank is connected to an ethanol tank, the outlet of the second concentration tank is connected to a second filter, the liquid phase outlet of the second filter is connected to a cooling tank, the outlet of the cooling tank is connected to a third filter, the solid phase outlet of the third filter is connected to a dissolving tank, the inlet of the dissolving tank is connected to a purified water tank, the outlet of the dissolving tank is connected to a crystallization tank, the outlet of the crystallization tank is connected to a centrifuge, the solid phase outlet of the centrifuge is connected to a dryer, and the outlet of the dryer is connected to a finished product tank. The process is simple, reduces production costs, and improves production efficiency.

The invention discloses a method for treating mother liquor in the preparation process of D-chiro-inositol, and relates to the technical field of D-chiro-inositol production.The D-chiro-inositol mother liquor is subjected to dealcoholization, acidification and adsorption and then subjected to segmented concentration, 50% ethyl alcohol is added into an obtained filter cake again for filtering, ethyl alcohol is added into collected filtrate, cooling is conducted, and finally a D-chiro-inositol crude product is obtained; the economic benefit is improved, and meanwhile, the method is environment-friendly.

The invention discloses a method for detecting the ratio of chiral inositol to inositol, and relates to the technical field of chiral inositol content detection.The method comprises the steps that chiral inositol, inositol and water are dissolved, at least five standard substance solutions with different ratios of chiral inositol to inositol and the same baume degree are prepared, and the value of the baume degree of each standard substance solution is recorded as Beb; determining the optical rotation of each standard substance solution; drawing a standard curve by taking the ratio of the chiral inositol to the inositol as a horizontal coordinate and the optical rotation of the corresponding standard substance solution as a vertical coordinate; the baume degree and the optical rotation of the sample solution are measured, the value of the baume degree of the sample solution is recorded as BeY, and the value of the optical rotation of the sample solution is recorded as A; when BeY is not equal to Beb, calculating the optical rotation B of the sample solution when the baume degree is Beb according to a formula I; formula I; substituting the optical rotation B into the standard curve to calculate the ratio of chiral inositol to inositol; the method is simple and fast, and has good accuracy.

The present invention relates to compositions for oral administration, suitable for supporting women with gyneacological syndromes, which comprise a) one or more inositol stereoisomers that contribute to the normal function of the ovaries, one of said inositol stereoisomers is necessarily myo-inositol, and when said composition also comprises D-chiro-inositol, the myo-inositol: D-chiro-inositol ratio ranges from 2:1 to 5:1, b) one or more vitamins, which are selected from one or more vitamins of the B complex, c) one or more additional active substances other than inositol stereoisomers and vitamins of the B complex, which are selected from one or more hormones involved in the normal function of the ovaries and / or one or more herbal extracts that contribute to the normal psychological function and / or one or more amino acids and d) one or more inactive excipients.

This invention relates to the field of genetic engineering technology, and particularly to a mixed enzyme preparation for the catalytic synthesis of D-chiral inositol and a method for preparing D-chiral inositol. The enzyme preparation comprises an inositol dehydrogenase mutant and a ketoisomerase mutant. The amino acid sequence of the inositol dehydrogenase mutant is altered by changing the 95th amino acid of the amino acid sequence shown in SEQ ID NO.1 from K to R, and / or changing the 124th amino acid of the amino acid sequence shown in SEQ ID NO.1 from R to K; the amino acid sequence of the inositol dehydrogenase mutant is altered by changing the 99th amino acid of the amino acid sequence shown in SEQ ID NO.3 from T to S; and / or changing the 213th amino acid of the amino acid sequence shown in SEQ ID NO.3 from D to N. This invention co-expresses the inositol dehydrogenase and ketoisomerase with specific site mutations, significantly improving the conversion rate of D-chiral inositol.

This invention discloses a high-fiber puffed grain powder and its preparation method, belonging to the field of food processing technology. By weight, it comprises the following raw materials: 25-35 parts whole barley flour, 20-30 parts whole oat flour, 15-25 parts whole buckwheat flour, 10-20 parts soybean residue powder, and 5-15 parts wheat bran powder. The whole buckwheat flour contains ≥0.8 mg / g of D-chiral inositol. This invention utilizes the aforementioned high-fiber puffed grain powder and its preparation method, employing a triple synergistic technology scheme of heat-resistant phytase and cellulase combined enzymatic hydrolysis, dry powder moisture adjustment, and low-temperature puffing. This achieves a significant increase in soluble dietary fiber content and a significant optimization of the SDF / IDF ratio, effectively improving mineral bioavailability. Furthermore, low-temperature puffing protects buckwheat flavonoids and D-chiral inositol, inhibits acrylamide formation, ensures product safety, and exhibits multi-target synergistic hypoglycemic effects.